Straus SM - Search Results

1

Rituximab-induced thrombocytopenia: a cohort study.

Giezen TJ, Mantel-Teeuwisse AK, ten Berg MJ, Straus SM, Leufkens HG, van Solinge WW, Egberts TC. Giezen TJ, et al. Among authors: straus sm. Eur J Haematol. 2012 Sep;89(3):256-66. doi: 10.1111/j.1600-0609.2012.01808.x. Epub 2012 Jul 5. Eur J Haematol. 2012. PMID: 22639923

2

Safety-related regulatory actions for biologicals approved in the United States and the European Union.

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Giezen TJ, et al. Among authors: straus sm. JAMA. 2008 Oct 22;300(16):1887-96. doi: 10.1001/jama.300.16.1887. JAMA. 2008. PMID: 18940975

3

Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs.

Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Leufkens HG, Egberts AC, Sturkenboom MC. Willemen MJ, et al. Among authors: straus sm. Pharmacoepidemiol Drug Saf. 2009 Jul;18(7):631-8. doi: 10.1002/pds.1759. Pharmacoepidemiol Drug Saf. 2009. PMID: 19415767

4

Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Egberts TC, Blackburn S, Persson I, Leufkens HG. Giezen TJ, et al. Among authors: straus sm. Drug Saf. 2009;32(12):1175-87. doi: 10.2165/11318980-000000000-00000. Drug Saf. 2009. PMID: 19916584

5

Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.

Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, Straus SM, Leufkens HG, Egberts TC. Giezen TJ, et al. Among authors: straus sm. Drug Saf. 2010 Oct 1;33(10):865-78. doi: 10.2165/11538330-000000000-00000. Drug Saf. 2010. PMID: 20812771

6

Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study.

Willemen MJ, Mantel-Teeuwisse AK, Buggy Y, Layton D, Straus SM, Leufkens HG, Egberts TC. Willemen MJ, et al. Among authors: straus sm. Drug Saf. 2012 Dec 1;35(12):1147-58. doi: 10.1007/BF03262000. Drug Saf. 2012. PMID: 23061737

7

Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.

Vermeer NS, Straus SM, Mantel-Teeuwisse AK, Domergue F, Egberts TC, Leufkens HG, De Bruin ML. Vermeer NS, et al. Among authors: straus sm. Drug Saf. 2013 Aug;36(8):617-25. doi: 10.1007/s40264-013-0073-3. Drug Saf. 2013. PMID: 23771794

8

Traceability of biologicals: present challenges in pharmacovigilance.

Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML. Vermeer NS, et al. Among authors: straus sm. Expert Opin Drug Saf. 2015 Jan;14(1):63-72. doi: 10.1517/14740338.2015.972362. Epub 2014 Nov 5. Expert Opin Drug Saf. 2015. PMID: 25369769 Review.

9

The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.

Vermeer NS, Ebbers HC, Straus SM, Leufkens HG, Egberts TC, De Bruin ML. Vermeer NS, et al. Among authors: straus sm. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):297-306. doi: 10.1002/pds.3929. Epub 2015 Dec 16. Pharmacoepidemiol Drug Saf. 2016. PMID: 26676881

10

Post-approval safety issues with innovative drugs: a European cohort study.

Mol PG, Arnardottir AH, Motola D, Vrijlandt PJ, Duijnhoven RG, Haaijer-Ruskamp FM, de Graeff PA, Denig P, Straus SM. Mol PG, et al. Among authors: straus sm. Drug Saf. 2013 Nov;36(11):1105-15. doi: 10.1007/s40264-013-0094-y. Drug Saf. 2013. PMID: 24048690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82 results

Search Page

Filters